Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis.

ABSTRACT:

Background

Atopic dermatitis (AD) is a common chronic eczematous skin disease with severe pruritus. Several new therapeutic agents for AD such as dupilumab, an anti-IL-4Rα antibody, have been developed in recent years. We need to predict which agent is the best choice for each patient, but this remains difficult.

Objective

Our aim was to examine clinical background factors and baseline biomarkers that could predict the achievement of improved clinical outcomes in patients with AD treated with dupilumab.

Methods

A multicenter, prospective observational study was conducted on 110 patients with AD. The Eczema Area and Severity Index was used as an objective assessment, and the Patient-Oriented Eczema Measure and Numerical Rating Scale for Pruritus were used as patient-re

SUBMITTER: Kido-Nakahara M 

PROVIDER: S-EPMC11381866 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature